NVILE forecast ·

Pfizer (PFE) Stock Forecast: Next 30 Days

Pfizer's calibrated 80% price range over the next 30 days is $27.95 to $33.47, against a last close of $30.40. The Q3 earnings release scheduled for November 3, 2026, represents the primary near-term catalyst. Recent earnings sessions showed an average single-day move of 1.6%, while options markets imply a 3.7% move. The probability of an earnings-day move exceeding 10% is under 0.1%, with a 30-day probability of 10% for a >10% gain versus 6% for a >10% decline.

Price now

$30.40

Nov 2, 2026

In 30 days

$30.59

NVILE forecast

Expected move

+0.6%

Range

$27.95–$33.47

$33.34$28.59$23.84Jun 26, 2026Today+30d

What to do

  • Maintain calibrated risk bounds between $27.95 and $33.47 when structuring short-term options or swing positions.Distribution models show modest directional drift but highlight defined boundaries covering 80% of projected price paths.
  • Factor in a 3.7% implied move and avoid unhedged directional exposure immediately prior to the November 3 earnings release.[11]Options contracts reflect heightened event-session repricing relative to the typical 1.6% historical results-day move.
  • Monitor post-earnings non-COVID sales traction against analyst price targets clustered around $28.65–$29.26.[5],[7],[9]With the stock trading near $30.40, failure to exceed lowered EPS bars could accelerate multiple convergence toward analyst targets.

Why

  • Pfizer enters Q3 earnings trading near its 52-week peak ($30.52 close) after an 11.1% recent advance, while Wall Street consensus 12-month targets average $28.65 to $29.26.[4],[5],[7]
  • Consensus Q3 EPS estimates were cut by 4.1% over 30 days and 10.2% over 90 days, lowering the hurdle despite four prior consecutive earnings beats.[7],[11]
  • Insider sentiment is net positive, highlighted by CEO Albert Bourla purchasing 38,000 shares ($26.34) and Director Ronald Blaylock adding 39,231 shares ($25.46) in August.[2]
  • Core product strength in Eliquis and newly acquired assets is balanced against declining revenues from COVID-19 therapies Comirnaty and Paxlovid.[8],[10]
  • Corporate cost-cutting initiatives targeting an additional $2.5 billion accompany a 12% year-over-year increase in R&D spending to bridge growth toward 2028.[6],[10]

What could go wrong

  • Top-line contraction of 4.8% YoY projected for Q3 due to steep declines in Paxlovid and Comirnaty demand could pressure valuations if non-COVID revenue lags.[5],[8]
  • Aggressive R&D cost-cutting could compromise long-term commercial innovation and pipeline replenishment before 2028 growth targets materialise.[6],[10]

How it connects

  • Albert Bourlaleads as Chairman and CEO and bought 38,000 sharesPfizer Inc.[10],[2]
  • Ronald E. Blaylockserves as Director and bought 39,231 sharesPfizer Inc.[2]
  • Jennifer B. Damicoserves as SVP & Controller and sold 3,278 sharesPfizer Inc.[2]
  • Pfizer Inc.holds joint historical consumer healthcare venture with GSKHaleon plc[3]
  • GSK plcpartnered with Pfizer in consumer healthcare joint ventureHaleon plc[3]
  • Pfizer Inc.markets and drives revenue growth fromEliquis[10]
  • Pfizer Inc.faces declining sales volume from lower infection rates forPaxlovid[8]
  • Pfizer Inc.experiences top-line headwinds from lower demand forComirnaty[8]
  • Louise Chencovers pharmaceutical equities forScotiabank[9]
  • Scotiabankboosted price target from $30.00 to $33.00 with Outperform ratingPfizer Inc.[9]
  • HSBCboosted price target from $28.00 to $30.00 with Hold ratingPfizer Inc.[9]
  • FINRApublishes Reg SHO short-sale volume reports forPfizer Inc.[1]
  • SECreceives statutory insider trading disclosures fromPfizer Inc.[2]

NVILE's track record on this page

MadeForecastActualResult
Nov 2, 2026$30.59Due Dec 2, 2026Pending
Oct 30, 2026$30.57Due Nov 29, 2026Pending

Every published call is scored when it comes due. See all results →

Sources

  1. 1.PFE daily short-sale volume (FINRA) · finra.org
  2. 2.PFIZER INC insider transactions (SEC Form 4) · sec.gov
  3. 3.PFIZER INC 10-K (2026-02-26) · sec.gov
  4. 4.PFE | Pfizer Inc. Stock Overview (U.S.: NYSE) | Barron's · barrons.com
  5. 5.What to expect from Pfizer's (PFE) Q3 earnings · theglobeandmail.com
  6. 6.Pfizer Inc (PFE) · morningstar.com
  7. 7.PFE Wall Street consensus: estimates, revisions, ratings, targets · finance.yahoo.com
  8. 8.Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy? · ca.finance.yahoo.com
  9. 9.Pfizer (PFE) Stock Forecast and Price Target 2026 $PFE · marketbeat.com
  10. 10.Pfizer beats earnings estimates, targets $2.5 billion in ... · reuters.com
  11. 11.Pfizer Shares Near 52-Week High Ahead of Earnings · tradingpedia.com

Questions

What is the Pfizer forecast for the next 30 days?

NVILE's models put Pfizer at about $30.59 in 30 days, +0.6% from $30.40. Pfizer's calibrated 80% price range over the next 30 days is $27.95 to $33.47, against a last close of $30.40. The Q3 earnings release scheduled for November 3, 2026, represents the primary near-term catalyst. Recent earnings sessions showed an average single-day move of 1.6%, while options markets imply a 3.7% move. The probability of an earnings-day move exceeding 10% is under 0.1%, with a 30-day probability of 10% for a >10% gain versus 6% for a >10% decline.

What price range does NVILE expect for Pfizer?

The forecast range is $27.95 to $33.47 over 30 days. Prices outside this range are possible; the range describes the model's scenarios, not a guarantee.

What could change the Pfizer outlook?

Top-line contraction of 4.8% YoY projected for Q3 due to steep declines in Paxlovid and Comirnaty demand could pressure valuations if non-COVID revenue lags. Aggressive R&D cost-cutting could compromise long-term commercial innovation and pipeline replenishment before 2028 growth targets materialise.

What should investors watch or do about Pfizer?

Maintain calibrated risk bounds between $27.95 and $33.47 when structuring short-term options or swing positions. Factor in a 3.7% implied move and avoid unhedged directional exposure immediately prior to the November 3 earnings release. Monitor post-earnings non-COVID sales traction against analyst price targets clustered around $28.65–$29.26.

How accurate are NVILE forecasts?

Every forecast NVILE publishes is scored against the real price when it comes due, and the results are listed on NVILE's public accuracy ledger.

This page is generated by NVILE's research models from public sources and market data. It is not financial advice, and forecasts can be wrong.